HCV Resistance Assay Using Segmented Genome Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays fail to accurately detect and characterize mutations in the Hepatitis C Virus (HCV) genome associated with drug resistance, leading to ineffective treatment outcomes and potential adverse effects due to resistance to anti-HCV drugs.
Innovation Solution
An assay that involves extracting viral RNA, determining HCV genotype and subtype, synthesizing partial cDNAs through reverse transcription, and amplifying them using specific primer pairs to identify and characterize mutations, with further nested PCR amplification and sequence analysis to compare with prototype HCV sequences, enabling the creation of a data bank for resistance mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current assays are used to detect HCV mutations, then the detection process is simple, but the detection precision and ability to characterize mutations is insufficient
Solution Approach 1:
The HCV genome is divided into multiple regions (5'UTR, Core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B, 3'UTR) and each region is amplified separately using region-specific primer pairs. This segmentation allows for precise detection and characterization of mutations in different genomic regions while maintaining a systematic and manageable assay structure.
2Reliability
If standard treatment is used for HCV infection, then the treatment protocol is straightforward, but the treatment efficacy is reduced due to drug resistance
Solution Approach 1:
The assay performs preliminary detection of resistance-associated mutations before treatment selection. By identifying mutations in advance using the multi-region amplification and sequencing approach, clinicians can select appropriate antiviral regimens that will be effective against the patient's specific HCV strain, thereby improving treatment efficacy while providing a systematic method for treatment planning.
3Measurement precision
If full genome sequencing is performed to detect all mutations, then the detection completeness is high, but the time and resource consumption increases significantly
Solution Approach 1:
Instead of sequencing the entire genome in one process, the assay segments the genome into 12 specific regions and amplifies them separately using multiple primer pairs. This allows for comprehensive mutation detection across the entire genome while reducing the complexity and time of each individual amplification reaction, making the overall process more efficient.
Solution Approach 2:
The assay focuses on amplifying and sequencing specific regions of the HCV genome that are most relevant for drug resistance detection, rather than performing complete whole-genome sequencing. This partial action approach detects all clinically relevant mutations while significantly reducing the time and computational resources required compared to full genome sequencing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for sensitive detection and characterization of individual and linked mutations, enabling the selection of appropriate anti-HCV drugs or drug combinations that the virus is not resistant to, improving treatment efficacy and reducing adverse effects.
Implementation Method 1
synthesis of partial cDNAs of the genome of the HCV in three separate reverse transcription reactions
Implementation Method 2
amplification of the partial cDNAs of step c) in three separate PCR reactions
Implementation Method 3
further amplification of the partial cDNAs of step d) in three separate nested PCR reactions
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.